48 computer-algorithm "https:" "Simons Foundation" Fellowship positions at UNIVERSITY OF SOUTHAMPTON
Sort by
Refine Your Search
-
We are delighted to welcome applications for a Research Fellow post within the ESRC Connecting Generations programme to examine intergenerational flows of support in later life and the increased
-
10 Jan 2026 Job Information Organisation/Company UNIVERSITY OF SOUTHAMPTON Research Field Computer science Researcher Profile First Stage Researcher (R1) Country United Kingdom Application Deadline
-
Jan 2026 - 00:00 (UTC) Type of Contract Other Job Status Full-time Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff position within
-
-intensive Universities (https://www.southampton.ac.uk/ ). We have an international reputation for research, teaching and enterprise activities. The job This is a part time (0.6 FTE) fixed appointment for a
-
for Selective Absorbers. Your primary role will be to undertake theoretical and computational research on hyperuniform disordered photonic materials for frequency-selective solar-thermal absorbers based on metal
-
Zamora-Gutierrez (https://www.southampton.ac.uk/people/65cf7s/doctor-veronica-zamora-gutierrez ). The position is fixed for 36 months (3 years). The postholder will lead research on bat ecology and the
-
biggest challenges. We are seeking a Research Fellow in Liquid Metal Artificial Enzymes to join the School of Electronics and Computer Science (ECS) at the University of Southampton. The successful
-
programme, Deep Molecular Phenotyping of Metastatic Breast Cancer. This ambitious, interdisciplinary project aims to generate an integrated, multi-omic understanding of secondary (metastatic) breast cancer
-
the project forward and translate our research into tangible innovations for the UK’s growing photonics sector, building upon our recent work published in Nature (https://www.nature.com/articles/s41586-025
-
postdoctoral scientist to work on our Blood Cancer UK-funded programme developing next-generation, off-the-shelf immunotherapies for acute myeloid leukaemia (AML). This three-year project will harness cytotoxic